EGFR-TKI (epidermal growth factor receptor-tyrosine kinase inhibitor) and ALK (anaplastic lymphoma kinase) inhibitors are the best of these developments and have changed clinical treatment mode of lung cancer, especially in the treatment of lung adenocarcinoma (LUAD) [4, 8–11]. Here, ALK is linked to lung adenocarcinoma.